InSilicoTrials
InSilicoTrials is a company dedicated to revolutionizing drug and medical device development through computational modeling and simulation. They aim to accelerate the development process, reduce costs, and improve safety by providing a user-friendly, cloud-based platform that enables in silico trials and supports personalized medicine. Their mission is to harness in silico technology to bring innovative, accessible, and safer therapies to market faster, contributing to better healthcare worldwide.
Industries
Nr. of Employees
small (1-50)
InSilicoTrials
Via delle Scienze 10, Bologna, Italy
Products
Cardiac-safety classifier combining electrophysiology simulation and machine learning
Integrated electrophysiology simulations and ML to classify drug-induced proarrhythmic risk using multi-channel in vitro inputs.
hiPSC-derived cardiomyocyte population simulator
Web-based in silico trials on populations of human iPSC-derived cardiomyocytes to assess ion-channel interactions and physiological variability.
Disease-specific treatment simulators (neurology models)
Mechanistic platforms that predict disease activity and personalized treatment effects for indications such as multiple sclerosis and ALS, usable for trial simulation and synthetic controls.
Structure-based interaction and epitope prediction tools
Computational tools for ligand–target interaction exploration and epitope prediction to support target validation, antigen selection and vaccine design.
ADME and BBB permeability prediction tools
In silico prediction of absorption, distribution, metabolism and elimination properties and blood–brain barrier crossing potential for small molecules to support early ADME profiling.
Particle and tablet-coating process simulators
Simulation tools for fluid–granular dynamics and tablet coating to determine process parameters such as coater speed, load and spray profiles for CMC applications.
Cardiac-safety classifier combining electrophysiology simulation and machine learning
Integrated electrophysiology simulations and ML to classify drug-induced proarrhythmic risk using multi-channel in vitro inputs.
hiPSC-derived cardiomyocyte population simulator
Web-based in silico trials on populations of human iPSC-derived cardiomyocytes to assess ion-channel interactions and physiological variability.
Disease-specific treatment simulators (neurology models)
Mechanistic platforms that predict disease activity and personalized treatment effects for indications such as multiple sclerosis and ALS, usable for trial simulation and synthetic controls.
Structure-based interaction and epitope prediction tools
Computational tools for ligand–target interaction exploration and epitope prediction to support target validation, antigen selection and vaccine design.
ADME and BBB permeability prediction tools
In silico prediction of absorption, distribution, metabolism and elimination properties and blood–brain barrier crossing potential for small molecules to support early ADME profiling.
Particle and tablet-coating process simulators
Simulation tools for fluid–granular dynamics and tablet coating to determine process parameters such as coater speed, load and spray profiles for CMC applications.
Services
On-demand access to a cloud platform for running validated computational models and retrieving reproducible, regulatory-oriented reports.
Design and run simulated clinical trials on virtual populations, including generation of synthetic control arms and statistical enrichment strategies.
FEA and CFD services to emulate nonclinical tests, device deployment and patient-specific hemodynamics for device development and planning.
Advisory services on verification/validation, reporting and alignment with regulatory guidance and Good Simulation Practice for submissions.
Simulation of pharmaceutical unit operations and particulate processes to optimize coating, mixing and scale-up parameters.
On-demand access to a cloud platform for running validated computational models and retrieving reproducible, regulatory-oriented reports.
Design and run simulated clinical trials on virtual populations, including generation of synthetic control arms and statistical enrichment strategies.
FEA and CFD services to emulate nonclinical tests, device deployment and patient-specific hemodynamics for device development and planning.
Advisory services on verification/validation, reporting and alignment with regulatory guidance and Good Simulation Practice for submissions.
Simulation of pharmaceutical unit operations and particulate processes to optimize coating, mixing and scale-up parameters.
Expertise Areas
- In silico clinical trial design and execution
- Computational pharmacology and ADME/PK prediction
- Cardiac safety and electrophysiology modeling
- Digital twin and patient-specific modeling
Key Technologies
- Cloud-based high-performance computing
- Finite Element Analysis (FEA)
- Computational Fluid Dynamics (CFD)
- Agent-based and multi-scale mechanistic modeling
News & Updates
Axoltis Pharma's phase 1b clinical trial of NX210c shows promising results, with plans for phase 2 trials in ALS and Parkinson's Disease, supported by InSilicoTrials' computational modeling.
Authorization from French agency ANSM to launch a phase II trial targeting ALS, with in silico modeling support from InSilicoTrials to predict disease progression.
Axoltis Pharma's phase 1b clinical trial of NX210c shows promising results, with plans for phase 2 trials in ALS and Parkinson's Disease, supported by InSilicoTrials' computational modeling.
Authorization from French agency ANSM to launch a phase II trial targeting ALS, with in silico modeling support from InSilicoTrials to predict disease progression.